- Contract Awards
The Food and Drug Administration has awarded Engility (NYSE: EGL) a potential five-year, $112 million indefinite-delivery/indefinite-quantity contract to provide computational science and bioinformatics services for the FDA’s gene-based drug discovery and development programs. Engility said Thursday it will help the FDA operate, secure an...


